Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Capital Leases: 2017-2018

  • KalVista Pharmaceuticals' Capital Leases was N/A to $58,000 in Q2 2018 from the same period last year, while for Apr 2018 it was $58,000, marking a year-over-year change of. This contributed to the annual value of $58,000 for FY2018, which is N/A change from last year.
  • Latest data reveals that KalVista Pharmaceuticals reported Capital Leases of $58,000 as of Q2 2018, which was down 50.43% from $117,000 recorded in Q1 2018.
  • In the past 5 years, KalVista Pharmaceuticals' Capital Leases registered a high of $213,000 during Q3 2017, and its lowest value of $58,000 during Q2 2018.
  • In the last 2 years, KalVista Pharmaceuticals' Capital Leases had a median value of $133,000 in 2017 and averaged $134,250.